Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Rational Analyst -- Ignore unavailable to you. Want to Upgrade?

To: Susan Saline who wrote (1015)	5/27/1998 11:41:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 1720

[Thanks for TTNP response and biotech clarification] Risk/reward with biotech is a 3 fold thing: TA, the sector, and combination of: the number of items in the pipeline the progress thru clinical trials (both safty and efficacy issues) cash burn rate/funds to fund clinical development and trials. I don't expect anyone else on this thread to assess the later portion (while if there were some biotech vets, I would always welcome additional perspective, my biotech expertise is a relative concept at best) But that is in essence the nature of the RA thread - trying to synch multiple modes of analysis,and people contributing in areas where they have expertise, while seeking to learn in some areas where they need to improve. Scott